TCS 3,255.25 -17.50 (-0.53%) 
HDFCBANK 1,897.35 +19.45 (1.04%) HINDUNILVR 2,354.30 -12.85 (-0.54%) INFY 1,397.00 -16.00 (-1.13%) HDFC 2,729.95 -17.05 (-0.62%) BHARTIARTL 1,874.15 +51.15 (2.81%) KOTAKBANK 2,133.30 +10.30 (0.49%) ICICIBANK 1,390.15 +33.40 (2.46%) ITC 424.85 +0.70 (0.17%) BAJFINANCE 9,042.55 -12.30 (-0.14%) MARUTI 11,671.00 +6.75 (0.06%) HCLTECH 1,415.00 -17.20 (-1.20%) SBIN 774.75 +3.00 (0.39%) NESTLEIND 2,408.60 +25.00 (1.05%) ASIANPAINT 2,467.70 +8.35 (0.34%) WIPRO 234.75 -12.75 (-5.15%) DMART 4,288.70 +66.70 (1.58%) AXISBANK 1,173.95 +12.40 (1.07%) LT 3,186.85 -41.30 (-1.28%) HDFCLIFE 716.05 +0.05 (0.01%) SUNPHARMA 1,727.40 +34.75 (2.05%) ULTRACEMCO 11,803.00 +76.20 (0.65%) ONGC 243.60 +2.40 (1.00%) BAJAJFINSV 1,981.00 +11.10 (0.56%) BPCL 299.10 +0.35 (0.12%) POWERGRID 307.20 +1.35 (0.44%) TITAN 3,292.00 +20.35 (0.62%) BRITANNIA 5,441.00 +27.20 (0.50%) NTPC 362.50 +3.20 (0.89%) Download Unicorn Signals App
By EquityPandit
Zydus Cadila, the drug firm has got the US health regulator’s approval for marketing Mirtazapine orally disintegrating tablets, an anti depressant, in the American market.
The company has said in a BSE filing that Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market the Mirtazapine orally disintegrating tablets USP in strengths 15mg, 30mg and 45mg.
The company is going to manufacture the product at its facility in Baddi.
